Onglyza

Onglyza

Manufacturer:

AstraZeneca

Distributor:

Zuellig Pharma

Marketer:

Zuellig Pharma
Concise Prescribing Info
Contents
Saxagliptin HCl
Indications/Uses
Adjunct to diet & exercise to improve glycaemic control in patients w/ type 2 DM.
Dosage/Direction for Use
2.5 or 5 mg once daily. Patient w/ moderate or severe renal impairment or end-stage renal disease requiring hemodialysis (CrCl ≤50 mL/min) & when co-administered w/ strong CYP3A4/5 inhibitors 2.5 mg once daily.
Administration
May be taken with or without food: Do not split/cut tab.
Contraindications
History of serious hypersensitivity reactions eg, anaphylaxis, angioedema or exfoliative skin conditions.
Special Precautions
Discontinue use if serious hypersensitivity reaction or pancreatitis, severe & disabling arthralgia or bullous pemphigoid is suspected. Not to be used in type 1 DM or diabetic ketoacidosis. Heart failure. Assess renal function prior to & periodically thereafter. Concomitant use of sulfonylurea or insulin. Pregnancy & lactation. Childn <18 yr. Elderly.
Adverse Reactions
Upper resp tract infection, UTI, headache, hypoglycemia, hypersensitivity reactions, acute pancreatitis, severe & disabling arthralgia.
Drug Interactions
Increased exposure by ketoconazole. Increased plasma conc w/ strong CYP3A4/5 inhibitors eg, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin.
MIMS Class
ATC Classification
A10BH03 - saxagliptin ; Belongs to the class of dipeptidyl peptidase 4 (DPP-4) inhibitors. Used in the treatment of diabetes.
Presentation/Packing
Form
Onglyza FC tab 5 mg
Packing/Price
28's
Form
Onglyza FC tab 2.5 mg
Packing/Price
28's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in